GURU.Markets stock price, segment price, and overall market index valuation
The company's share price CorMedix Inc.
Shares of CorMedix, a biopharmaceutical company, are driven by the commercial success of its flagship product, DefenCath, which prevents catheter infections. The price chart reflects the long road to FDA approval and subsequent investor expectations for the pace of its adoption in hospitals.
Share prices of companies in the market segment - Pharma infections
CorMedix (CRMD) is a biopharmaceutical company focused on the development and commercialization of therapeutics for the prevention and treatment of infectious and inflammatory diseases. We have classified it in the Pharmaceuticals/Infections segment. The chart below illustrates the dynamics of this important healthcare sector.
Broad Market Index - GURU.Markets
CorMedix is a biopharmaceutical company that developed the antibacterial solution DefenCath for the prevention of catheter-associated bloodstream infections. As a component of the GURU.Markets index, it addresses an important medical need. The chart below represents the entire market. See how CorMedix shares compare to the overall trend.
Change in the price of a company, segment, and market as a whole per day
CRMD - Daily change in the company's share price CorMedix Inc.
For CorMedix, a biopharmaceutical company, change_co is a measure of the sector's inherently high volatility. Each daily change reflects its sensitivity to news about the commercialization of its products. This metric isn't just noise, but a critical component of the models on System.GURU.Markets that assess biotech risk.
Daily change in the price of a set of shares in a market segment - Pharma infections
CorMedix Inc. is a pharmaceutical company. This chart highlights the sector's high volatility. Comparing it to CRMD, whose success hinges on a single infection-preventing drug, helps to understand its high concentration risks.
Daily change in the price of a broad market stock, index - GURU.Markets
CorMedix is a biopharmaceutical company specializing in drugs to prevent catheter-related infections. Biotechnology is a volatile sector. The chart below shows average daily fluctuations in this sector, providing context for analyzing CorMedix's stock performance.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization CorMedix Inc.
CorMedix is a biopharmaceutical company focused on infectious diseases. Its year-over-year performance reflects both the commercial success of its existing drugs and investor confidence in its R&D platform, which is focused on new breakthrough products.
Annual dynamics of market capitalization of the market segment - Pharma infections
CorMedix Inc. is a biopharmaceutical company focused on the prevention and treatment of catheter-associated infections. Its success depends on the commercialization of its key product. The chart below shows how its narrow focus and regulatory decisions impact its volatile performance within the pharmaceutical sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
CorMedix is a biopharmaceutical company whose stock performance is driven by the commercialization of its products and progress in research. The company's business is not dependent on economic cycles. The chart reflects biotech events rather than macroeconomic data, making it a non-cyclical growth story.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization CorMedix Inc.
The market capitalization of CorMedix, a biopharmaceutical company, depends on its product cycle. The monthly fluctuations on the chart reflect the commercial launch of its key product, Defencath, for the prevention of catheter-related infections, the success of which determines the company's future.
Monthly dynamics of market capitalization of the market segment - Pharma infections
Biopharmaceutical companies bringing new drugs to market to prevent infections are moving from R&D to the commercial stage. The dynamics of this sector, reflected in the chart, illustrate how investors evaluate the potential of a market launch. This provides context for a company like CorMedix.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
CorMedix Inc. is a biotech company fighting catheter-associated infections. Its shares are constantly awaiting news: clinical trial results and FDA decisions. The company's monthly performance is completely uncorrelated with the market, demonstrating sharp swings on events that shape its future.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization CorMedix Inc.
Shares of CorMedix, a biopharmaceutical company with a key infection prevention product, have been experiencing high volatility on a weekly basis. News about the pace of its hospital adoption, as well as sales data, are causing a sharp reaction from investors.
Weekly dynamics of market capitalization of the market segment - Pharma infections
CorMedix and the entire single-product biotech sector are moving against a backdrop of expectations and regulatory news. Investor sentiment toward such companies creates high volatility. The chart will show how the company's shares are reacting to this general "noise."
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Biotech companies like CorMedix often live in their own world, isolated from broader market fluctuations. Their stock price is determined by FDA news, not inflation reports. This chart shows how often unique company news allows its stock to move against the broader market tide.
Market capitalization of the company, segment and market as a whole
CRMD - Market capitalization of the company CorMedix Inc.
CorMedix's market capitalization is the financial valuation of the biotech company whose product, DefenCath, is designed to prevent catheter-associated bloodstream infections. The chart reflects the long and arduous path to FDA approval. Its recent performance is an attempt by investors to assess the product's commercial potential once it reaches market.
CRMD - Share of the company's market capitalization CorMedix Inc. within the market segment - Pharma infections
CorMedix Inc. develops antibacterial and antifungal solutions to prevent catheter-associated infections. Its market share is based on this important product. The chart shows how the market perceives its potential to solve one of the most common and dangerous hospital-acquired problems.
Market capitalization of the market segment - Pharma infections
CorMedix develops antibacterial solutions to prevent catheter-associated infections. The chart below shows the overall market capitalization of the sector. Its dynamics reflect the urgent need to combat hospital-acquired infections, where CorMedix's product could become a new standard.
Market capitalization of all companies included in a broad market index - GURU.Markets
Combating hospital-acquired infections is a critical challenge, as illustrated by the graph. CorMedix Inc. has developed an antibacterial solution to prevent catheter-associated infections. Its capitalization is a risky bet on the approval and commercial success of this product.
Book value capitalization of the company, segment and market as a whole
CRMD - Book value capitalization of the company CorMedix Inc.
CorMedix's schedule represents capital for the fight against catheter-associated infections. The company's book value at the development and commercialization stage consists of financial reserves and production assets. These funds are used to bring its lead product, DefenCath, to market.
CRMD - Share of the company's book capitalization CorMedix Inc. within the market segment - Pharma infections
CorMedix, a biopharmaceutical company, is preparing to commercialize its product. Its share of the sector's assets, consisting of R&D and manufacturing capacity, will grow. This chart shows how the company is building the physical foundation for commercializing its antimicrobial catheter lock.
Market segment balance sheet capitalization - Pharma infections
CorMedix develops antibacterial drugs. Pharmaceuticals, as the graph shows, are both knowledge- and capital-intensive. CorMedix focuses on developing its core product, and its capital is its intellectual property and clinical trial data.
Book value of all companies included in the broad market index - GURU.Markets
CorMedix Inc. is a biopharmaceutical company focused on the prevention and treatment of infections. Its book value reflects the capital invested in obtaining approval and launching its lead product, DefenCath, for the prevention of catheter-associated infections.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - CorMedix Inc.
CorMedix is a biopharmaceutical company. Its market capitalization is a premium to its cash flow, reflecting the commercial potential of its FDA-approved infection prevention product, DefenCath.
Market to book capitalization ratio in a market segment - Pharma infections
CorMedix develops antibacterial drugs to prevent catheter-related infections. The company's success depends on the approval and commercialization of its products. The chart shows how investor expectations for this potential compare with its current balance sheet assets.
Market to book capitalization ratio for the market as a whole
CorMedix is a biopharmaceutical company that has developed an antibacterial solution to prevent catheter-related infections. Compared to the average market valuations shown in this chart, its valuation is based on the commercial potential of its approved product and its ability to successfully bring it to market.
Debts of the company, segment and market as a whole
CRMD - Company debts CorMedix Inc.
CorMedix is a biopharmaceutical company focused on the prevention and treatment of catheter-associated infections. As it seeks commercialization of its lead product, the company incurs significant expenses for clinical trials and FDA approval. This chart illustrates how the company is funding its activities during this critical development phase.
Market segment debts - Pharma infections
CorMedix is a biopharmaceutical company focused on preventing catheter-associated infections. After receiving approval for its first product, the company enters the commercialization phase. This process requires marketing and manufacturing costs. This chart shows how the company finances its drug launch.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio CorMedix Inc.
CorMedix Inc. is a biopharmaceutical company developing drugs to prevent catheter-related infections. This chart shows how dependent it is on external funding. For a company whose success depends on regulatory approval and commercial launch, debt is a significant risk factor for investors.
Market segment debt to market segment book capitalization - Pharma infections
CorMedix is a biopharmaceutical company focused on the prevention and treatment of catheter-associated infections. Bringing antimicrobial drugs to market is a complex process. This chart shows the overall debt burden in the pharmaceutical industry. It helps assess how the company is funding its clinical trials and preparation for commercialization.
Debt to book value of all companies in the market
CorMedix Inc. is a biopharmaceutical company focused on preventing catheter-related infections. On the cusp of commercializing its core product, the company needs funding for marketing. This chart shows how accessible the debt market is compared to the more traditional biotech equity financing.
P/E of the company, segment and market as a whole
P/E - CorMedix Inc.
This chart shows the valuation of CorMedix, a biopharmaceutical company focused on infection prevention. Its P/E (if established) will be based on the success of its core product. This is a measure of investors' belief that the company will be able to carve out a niche in the market and that its product will become a standard in hospital practice.
P/E of the market segment - Pharma infections
CorMedix is a biopharmaceutical company specializing in the development and commercialization of therapeutic drugs for the prevention and treatment of infectious and inflammatory diseases. This chart shows the average valuation for the sector, providing investors with context for assessing CorMedix's scientific potential and commercial prospects.
P/E of the market as a whole
CorMedix is a biopharmaceutical company whose main product, Defencath, is designed to prevent catheter-associated bloodstream infections. Its valuation is entirely dependent on the commercial success of this product. The overall market sentiment reflected in this chart is irrelevant compared to sales data and the product's acceptance by the medical community.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company CorMedix Inc.
CorMedix Inc. is a biopharmaceutical company focused on the development and commercialization of anti-infective drugs. Its key product is designed to prevent catheter-associated bloodstream infections. This chart reflects investor expectations regarding the successful launch of the product and its future commercial potential.
%20P%2FE%20CorMedix%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-CorMedix-Inc.&v=1772627108814 "Chart of the company's future (projected) P/E CorMedix Inc.")
Future (projected) P/E of the market segment - Pharma infections
CorMedix is a biopharmaceutical company focused on the prevention and treatment of infections and inflammation. Their primary product is designed to prevent catheter-associated bloodstream infections. The chart reflects average profitability expectations for the biotech sector. CRMD's position relative to this benchmark reflects the market's assessment of their drug's potential to become a standard of care.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20infections&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-infections&v=1772627108817 "Future (projected) P/E graph of the market segment - Pharma infections")
Future (projected) P/E of the market as a whole
CorMedix Inc. is a biopharmaceutical company developing drugs to prevent catheter-related infections. Its valuation depends on the successful commercialization of its product. This overall market sentiment chart is important because it shows how willing investors are to fund the launch of new medical solutions.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772627108822 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit CorMedix Inc.
CorMedix Inc. is a biopharmaceutical company focused on the development and commercialization of antibacterial and antifungal drugs. Its financial chart reflects its path to profitability through FDA approval of its product, Defencath, and its subsequent launch in the market for the prevention of bloodstream infections.
Profit of companies in the market segment - Pharma infections
CorMedix Inc. is a biopharmaceutical company focused on the development and commercialization of antibacterial and antifungal drugs to prevent catheter-associated infections. This chart represents the total revenue for its segment. It demonstrates how successfully the industry as a whole is addressing the problem of hospital-acquired infections and commercializing new preventative treatments.
Overall market profit
CorMedix Inc. is developing antibacterial drugs to prevent catheter-related infections. Like many development-stage biotech companies, its valuation depends more on the success of clinical trials than on general economic cycles. However, the positive backdrop seen in this chart makes it easier to raise capital to complete the research.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company CorMedix Inc.
CorMedix Inc. is a biopharmaceutical company focused on the development and commercialization of antibacterial and antifungal drugs. Its lead product is designed to prevent bloodstream infections in hemodialysis patients. This chart reflects analyst expectations for the commercial success of this important hospital hygiene product.
%20profit%20of%20the%20company%20CorMedix%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-CorMedix-Inc.&v=1772627108849 "Graph of future (projected) profit of the company CorMedix Inc.")
Future (predicted) profit of companies in the market segment - Pharma infections
CorMedix is developing antibacterial solutions to prevent bloodstream infections in patients with kidney failure undergoing hemodialysis. The company's future depends on the approval and commercial success of its key product. This chart reflects forecasts for the entire pharmaceutical sector, helping to assess CorMedix's potential to address this serious medical need.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20infections&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-infections&v=1772627108874 "Graph of future (predicted) profits of companies in a market segment - Pharma infections")
Future (predicted) profit of the market as a whole
CorMedix Inc. is a pharmaceutical company developing drugs to prevent catheter-associated infections. Its success depends on regulatory approval and clinical implementation. The overall economic projections shown in this chart are of minimal significance for the company at this stage.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772627108877 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - CorMedix Inc.
CorMedix develops antibacterial solutions to prevent catheter-associated infections. The company is attracting considerable attention as it nears the commercialization stage of its key product. This chart reflects investors' confidence that its product will become a standard of care and capture a significant market share.
P/S market segment - Pharma infections
CorMedix Inc. is a biopharmaceutical company focused on the development and commercialization of antibacterial and antifungal drugs. Its key product is designed to prevent catheter-related infections. Future revenue depends on the success of this product. This chart for the pharmaceutical sector provides an overview of investor expectations for CorMedix's potential.
P/S of the market as a whole
CorMedix is a biopharmaceutical company focused on the development and commercialization of antibacterial and antifungal drugs to prevent catheter-associated infections. This revenue valuation chart is important for understanding how investors view the company's potential product, which aims to address the serious problem of hospital-acquired infections.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company CorMedix Inc.
CorMedix is a biopharmaceutical company focused on the development and commercialization of antibacterial and antifungal drugs to prevent catheter-associated infections. This chart shows how investors estimate the future sales of its flagship product, reflecting their expectations for its adoption in hospital practice.
%20P%2FS%20CorMedix%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-CorMedix-Inc.&v=1772627108906 "The graph of the company's future (projected) P/S CorMedix Inc.")
Future (projected) P/S of the market segment - Pharma infections
CorMedix Inc. is a biopharmaceutical company that developed Defencath, an antibacterial and antifungal solution for the prevention of catheter-associated bloodstream infections in hemodialysis patients. The company's valuation reflects investors' expectations for the commercial success of this product following FDA approval.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20infections&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-infections&v=1772627108909 "Future (projected) P/S market segment graph - Pharma infections")
Future (projected) P/S of the market as a whole
CorMedix Inc. develops antibacterial drugs to prevent catheter-related infections. The company aims to address a serious medical problem. In the context of the overall revenue projections shown in the chart, CorMedix represents a biotech company with a targeted product.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772627108917 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales CorMedix Inc.
CorMedix is a biopharmaceutical company whose flagship product, DefenCath, is designed to prevent catheter-associated bloodstream infections in hemodialysis patients. This graph represents the initial or expected revenue from sales of this drug after its commercial launch. Success depends on market acceptance and insurance coverage.
Sales of companies in the market segment - Pharma infections
CorMedix (CRMD) is a biopharmaceutical company focused on the development and commercialization of antibacterial and antifungal drugs. Its lead product, Defencath, is designed to prevent catheter-associated bloodstream infections. This chart shows revenue for the pharmaceutical sector, where CorMedix addresses the serious problem of hospital-acquired infections.
Overall market sales
CorMedix Inc. develops antibacterial drugs to prevent catheter-associated infections. While the need for such products is driven by medical needs, the economic environment plays a role. This graph, reflecting the overall economic situation, impacts hospital funding and their ability to implement new, more effective, but also more expensive, preventative measures.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company CorMedix Inc.
CorMedix Inc. is a biopharmaceutical company focused on the development and commercialization of anti-infective and anti-inflammatory drugs. Its primary product is designed to prevent catheter-associated bloodstream infections. This chart reflects analyst sales forecasts, which are an assessment of the success of the product's market launch and its acceptance by the medical community.
%20sales%20of%20the%20company%20CorMedix%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-CorMedix-Inc.&v=1772627108951 "Schedule of future (projected) sales of the company CorMedix Inc.")
Future (projected) sales of companies in the market segment - Pharma infections
CorMedix is a biopharmaceutical company focused on the development and commercialization of therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The forecast in this chart reflects the potential revenue of their flagship product, Defencath, demonstrating analysts' assessment of its market potential.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20infections&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-infections&v=1772627108968 "Schedule of future (projected) sales of companies in the market segment - Pharma infections")
Future (projected) sales of the market as a whole
CorMedix is a biopharmaceutical company focused on the development and commercialization of anti-infective drugs for use in hospitals. The company's success depends on regulatory approval and hospital acceptance of its product. This timeline, reflecting the state of the healthcare system, influences hospitals' readiness to implement new infection prevention drugs.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772627108984 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality CorMedix Inc.
CorMedix Inc. is a biopharmaceutical company focused on the development and commercialization of anti-infective and anti-inflammatory drugs. Its lead product, Defencath, is designed to prevent catheter-associated infections. The chart shows the company's financial performance at the product launch stage, where future profitability depends on its success.
Market segment marginality - Pharma infections
CorMedix is a biopharmaceutical company focused on the development and commercialization of anti-infective and anti-inflammatory drugs. Its key product, Defencath, is designed to prevent catheter-associated bloodstream infections. This graph shows the company's path to profitability after receiving FDA approval.
Market marginality as a whole
CorMedix Inc. is a pharmaceutical company developing anti-infective drugs for patients with catheters. The success of its product depends on its adoption in clinical practice. This overall profitability chart reflects the state of the healthcare system. Financially stable hospitals are more actively implementing new drugs aimed at reducing complications and long-term costs.
Employees in the company, segment and market as a whole
Number of employees in the company CorMedix Inc.
CorMedix is a biopharmaceutical company focused on preventing catheter-associated infections. As it nears commercialization of its lead product, its team is growing. This chart shows how the company is hiring sales and marketing specialists to prepare for the market launch.
Share of the company's employees CorMedix Inc. within the market segment - Pharma infections
CorMedix is a biopharmaceutical company focused on the prevention and treatment of catheter-associated infections. On the cusp of commercializing its core product, the company is actively hiring. This timeline reflects its transformation from an R&D startup to an operating company building commercial and manufacturing infrastructure.
Number of employees in the market segment - Pharma infections
CorMedix Inc. focuses on the prevention and treatment of catheter-associated infections. Employment trends in the infectious disease pharmaceutical sector demonstrate the relevance of this problem. For CorMedix, growth in this area underscores the need for hospitals to use their DefenCath product to reduce the risk of costly and dangerous complications.
Number of employees in the market as a whole
CorMedix is a biopharmaceutical company specializing in the prevention and treatment of infectious and inflammatory diseases. Its hiring is contingent on events such as clinical trial results and regulatory approvals. It recruits specialized talent from a larger pool of life sciences professionals.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company CorMedix Inc. (CRMD)
CorMedix is a biopharmaceutical company focused on the development and commercialization of antibacterial drugs to prevent catheter-associated infections. This figure reflects market expectations for its flagship product, Defencath. The high cost per employee indicates the product's potential to become a standard of care.
%20of%20the%20company%20CorMedix%20Inc.%20(CRMD)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-CorMedix-Inc.-CRMD&v=1772627109077 "Chart of market capitalization per employee (in thousands of dollars) of the company CorMedix Inc. (CRMD)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma infections
CorMedix develops antibacterial drugs to prevent catheter-related infections. In biotech, value is determined by the potential of a single key product. This chart illustrates the enormous future value the market places on the work of a small team that can solve a serious medical problem.
%20by%20market%20segment%20-%20Pharma%20infections&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-infections&v=1772627109092 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma infections")
Market capitalization per employee (in thousands of dollars) for the overall market
CorMedix is a biopharmaceutical company focused on the prevention and treatment of catheter-associated infections. The chart reflects the valuation of a company close to commercializing its key product. The high cost per employee indicates that the market is pricing in future revenue from sales of this hospital-critical drug.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772627109098 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company CorMedix Inc. (CRMD)
CorMedix is a biopharmaceutical company that developed Defencath, an antimicrobial drug for the prevention of catheter-related infections. Following recent FDA approval, the company is now in the early stages of commercialization. This timeline will show how successfully their team is bringing this niche, yet important, hospital product to market.
%20Chart%20CorMedix%20Inc.%20(CRMD)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-CorMedix-Inc.-CRMD&v=1772627109112 "Company Profit Per Employee (in thousands of dollars) Chart CorMedix Inc. (CRMD)")
Profit per employee (in thousands of dollars) in the market segment - Pharma infections
CorMedix is a biopharmaceutical company that developed Defencath/Neutrolin, an antimicrobial solution for the prevention of catheter-associated infections. Following FDA approval, the company is now in the early stages of commercialization. This metric (currently negative) will reflect the transition from R&D expenditures to sales revenue generation.
%20in%20the%20market%20segment%20-%20Pharma%20infections&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-infections&v=1772627109115 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma infections")
Profit per employee (in thousands of dollars) for the market as a whole
CorMedix Inc. is a biopharmaceutical company that developed Defencath/Neutrolin, an antimicrobial solution for the prevention of catheter-associated infections. It's a highly specialized product. This chart is important to understand that in biotech, even with an approved product, profit per employee can be low during the commercialization phase while the company ramps up sales and marketing.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772627109118 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee CorMedix Inc. (CRMD)
CorMedix is a biopharmaceutical company focused on the prevention and treatment of catheter-associated infections. Following the approval of its product, Defencath®, revenue per employee became a key metric for its commercial launch. This chart will reflect the company's success in bringing this important drug to market.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-CorMedix-Inc.-CRMD&v=1772627109137 "Sales chart per company employee CorMedix Inc. (CRMD)")
Sales per employee in the market segment - Pharma infections
CorMedix (CRMD) is a biopharmaceutical company that developed Defencath, an antimicrobial solution for the prevention of catheter-associated infections. This chart shows the average revenue per employee in the segment. It helps assess how effectively CorMedix is commercializing its key product with its team.
Sales per employee for the market as a whole
CorMedix (CRMD) is a biopharmaceutical company focused on the development and commercialization of antibacterial and antifungal solutions. Their key product is designed to prevent catheter-related infections. This metric reflects the company's transition from R&D to sales. As commercialization progresses, it should increase, demonstrating the effectiveness of monetizing their key product.
Short shares by company, segment and market as a whole
Shares shorted by company CorMedix Inc. (CRMD)
CorMedix (CRMD) is a biotech company focused on preventing catheter-related bloodstream infections. Its key product, Defencath, has been a long road to approval. This chart shows bearish sentiment. The increase in short positions may reflect investor doubts about Defencath's commercial success after its launch, concerns about manufacturing issues, or competition. (344)
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-CorMedix-Inc.-CRMD&v=1772627109208 "Short Shares Chart for the Company CorMedix Inc. (CRMD)")
Shares shorted by market segment - Pharma infections
CorMedix developed Defencath, an antibacterial "lock" for catheters that prevents infections in dialysis patients. This chart reflects the overall sentiment in the sector. It reflects investor skepticism toward single-product biotechs seeking to change hospital care standards.
Shares shorted by the overall market
CorMedix (CRMD) is a biopharmaceutical company focused on treating catheter-associated infections. Their key drug, Defencath, has had a long road to approval. This chart reflects concerns about commercial success. Bears may not believe the drug will be widely adopted by hospitals or that its price will be sufficient to cover marketing and manufacturing costs.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator CorMedix Inc. (CRMD)
CorMedix is a biotech company that received approval for its flagship product, Defencath, to prevent catheter infections. This chart measures investor expectations for the commercial launch. It shows when the stock is "overbought" on the hype of FDA approval or "oversold" on concerns about a slow sales launch.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-CorMedix-Inc.-CRMD&v=1772627109417 "RSI 14 indicator chart for the company's stock CorMedix Inc. (CRMD)")
RSI 14 Market Segment - Pharma infections
CorMedix is a biopharmaceutical company that developed Defencath (formerly Neutrolin), an antibacterial solution for catheters designed to prevent life-threatening bloodstream infections in dialysis patients. This chart reflects the overall sentiment in the biotech sector, helping to gauge how the market views this speculative industry.
RSI 14 for the overall market
CorMedix (CRMD) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast CRMD (CorMedix Inc.)
CorMedix (CRMD) is a biopharmaceutical company focused on preventing catheter-related infections with its flagship product. This chart shows the average target price. It reflects the collective analyst consensus on the commercial success of this drug's launch and its potential in the hospital infection market.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-CRMD-CorMedix-Inc.&v=1772627109523 "A chart showing analyst consensus forecasts for the expected stock price. CRMD (CorMedix Inc.)")
The difference between the consensus estimate and the actual stock price CRMD (CorMedix Inc.)
CorMedix is a biopharmaceutical company whose flagship product, Defencath, is designed to prevent life-threatening catheter infections. This chart measures the gap between the current price and the consensus target price. It shows the commercial potential (blockbuster or niche success) analysts see for this drug after its launch.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-CRMD-CorMedix-Inc.&v=1772627109525 "A chart showing the difference between the consensus forecast and the actual stock price. CRMD (CorMedix Inc.)")
Analyst consensus forecast for stock prices by market segment - Pharma infections
CorMedix is a biopharmaceutical company that developed Defencath, a drug for preventing dangerous bloodstream infections in dialysis patients. This chart shows analysts' overall expectations for the entire pharmaceutical sector (infectious diseases). It reflects whether experts believe there will be demand for new anti-infective solutions.
Analysts' consensus forecast for the overall market share price
CorMedix is a biopharmaceutical company focused on preventing catheter-related infections, particularly in dialysis patients (DefenCath). This chart shows overall market sentiment. For CorMedix, which is launching a new product, it's important to understand how these expectations (hospital budgets) impact the adoption of their life-saving, novel therapy. (350)
AKIMA index of the company, segment and market as a whole
AKiMA Company Index CorMedix Inc.
CorMedix (CRMD) is a biopharmaceutical company focused on solving a serious problem: catheter-related infections in dialysis patients. Their flagship product (Defencath) is designed to prevent these deadly infections. This chart is a commercialization indicator, reflecting the market's confidence in their ability to successfully bring this niche, yet critically important, product to market.
AKIMA Market Segment Index - Pharma infections
CorMedix (CRMD) is a single-product biotech focused on a critical unmet need; the company developed DefenCath, the first (and only) FDA-approved antibacterial solution for preventing blood clots in dialysis patients. This summary metric evaluates R&D. The graph shows the segment average. This benchmark: how does this niche monopoly (CRMD) differentiate itself from the average pharma company?
The AKIM Index for the overall market
CorMedix is a biopharmaceutical company commercializing DefenCath, a drug to prevent infections in dialysis patients. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this product launch in the "defense" healthcare sector compares to the overall economic trends that influence the adoption of new therapies.
